These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 12204691

  • 21. The σ-hole phenomenon of halogen atoms forms the structural basis of the strong inhibitory potency of C5 halogen substituted glucopyranosyl nucleosides towards glycogen phosphorylase b.
    Kantsadi AL, Hayes JM, Manta S, Skamnaki VT, Kiritsis C, Psarra AM, Koutsogiannis Z, Dimopoulou A, Theofanous S, Nikoleousakos N, Zoumpoulakis P, Kontou M, Papadopoulos G, Zographos SE, Komiotis D, Leonidas DD.
    ChemMedChem; 2012 Apr; 7(4):722-32. PubMed ID: 22267166
    [Abstract] [Full Text] [Related]

  • 22. Bioactivity of glycogen phosphorylase inhibitors that bind to the purine nucleoside site.
    Hampson LJ, Arden C, Agius L, Ganotidis M, Kosmopoulou MN, Tiraidis C, Elemes Y, Sakarellos C, Leonidas DD, Oikonomakos NG.
    Bioorg Med Chem; 2006 Dec 01; 14(23):7835-45. PubMed ID: 16908161
    [Abstract] [Full Text] [Related]

  • 23. Synthesis, screening and docking of small heterocycles as glycogen phosphorylase inhibitors.
    Schweiker SS, Loughlin WA, Lohning AS, Petersson MJ, Jenkins ID.
    Eur J Med Chem; 2014 Sep 12; 84():584-94. PubMed ID: 25062009
    [Abstract] [Full Text] [Related]

  • 24. A new allosteric site in glycogen phosphorylase b as a target for drug interactions.
    Oikonomakos NG, Skamnaki VT, Tsitsanou KE, Gavalas NG, Johnson LN.
    Structure; 2000 Jun 15; 8(6):575-84. PubMed ID: 10873856
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of designed ligands by a multiple screening method: application to glycogen phosphorylase inhibitors constructed with a variety of approaches.
    So SS, Karplus M.
    J Comput Aided Mol Des; 2001 Jul 15; 15(7):613-47. PubMed ID: 11688944
    [Abstract] [Full Text] [Related]

  • 26. Recent advances in the allosteric inhibition of glycogen phosphorylase.
    Loughlin WA.
    Mini Rev Med Chem; 2010 Oct 15; 10(12):1139-55. PubMed ID: 20716052
    [Abstract] [Full Text] [Related]

  • 27. The glycogen phosphorylase inhibitor 2-(3-benzylamino-2-oxo-1,2-dihydropyridin-1-yl)-N-(3,4-dichlorobenzyl)acetamide.
    Popova I, Healy PC, Loughlin WA, Karis ND, Jenkins ID.
    Acta Crystallogr C; 2013 Nov 15; 69(Pt 11):1408-10. PubMed ID: 24192198
    [Abstract] [Full Text] [Related]

  • 28. Activation of human liver glycogen phosphorylase by alteration of the secondary structure and packing of the catalytic core.
    Rath VL, Ammirati M, LeMotte PK, Fennell KF, Mansour MN, Danley DE, Hynes TR, Schulte GK, Wasilko DJ, Pandit J.
    Mol Cell; 2000 Jul 15; 6(1):139-48. PubMed ID: 10949035
    [Abstract] [Full Text] [Related]

  • 29. Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.
    Kristiansen M, Andersen B, Iversen LF, Westergaard N.
    J Med Chem; 2004 Jul 01; 47(14):3537-45. PubMed ID: 15214781
    [Abstract] [Full Text] [Related]

  • 30. Glucose-based spiro-isoxazolines: a new family of potent glycogen phosphorylase inhibitors.
    Benltifa M, Hayes JM, Vidal S, Gueyrard D, Goekjian PG, Praly JP, Kizilis G, Tiraidis C, Alexacou KM, Chrysina ED, Zographos SE, Leonidas DD, Archontis G, Oikonomakos NG.
    Bioorg Med Chem; 2009 Oct 15; 17(20):7368-80. PubMed ID: 19781947
    [Abstract] [Full Text] [Related]

  • 31. The structure of brain glycogen phosphorylase-from allosteric regulation mechanisms to clinical perspectives.
    Mathieu C, Dupret JM, Rodrigues Lima F.
    FEBS J; 2017 Feb 15; 284(4):546-554. PubMed ID: 27782369
    [Abstract] [Full Text] [Related]

  • 32. Binding evaluation of fragment-based scaffolds for probing allosteric enzymes.
    Krimm I, Lancelin JM, Praly JP.
    J Med Chem; 2012 Feb 09; 55(3):1287-95. PubMed ID: 22229710
    [Abstract] [Full Text] [Related]

  • 33. Crystallographic studies on acyl ureas, a new class of glycogen phosphorylase inhibitors, as potential antidiabetic drugs.
    Oikonomakos NG, Kosmopoulou MN, Chrysina ED, Leonidas DD, Kostas ID, Wendt KU, Klabunde T, Defossa E.
    Protein Sci; 2005 Jul 09; 14(7):1760-71. PubMed ID: 15987904
    [Abstract] [Full Text] [Related]

  • 34. Novel thienopyrrole glycogen phosphorylase inhibitors: synthesis, in vitro SAR and crystallographic studies.
    Whittamore PR, Addie MS, Bennett SN, Birch AM, Butters M, Godfrey L, Kenny PW, Morley AD, Murray PM, Oikonomakos NG, Otterbein LR, Pannifer AD, Parker JS, Readman K, Siedlecki PS, Schofield P, Stocker A, Taylor MJ, Townsend LA, Whalley DP, Whitehouse J.
    Bioorg Med Chem Lett; 2006 Nov 01; 16(21):5567-71. PubMed ID: 16945526
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments.
    Somsák L, Nagya V, Hadady Z, Docsa T, Gergely P.
    Curr Pharm Des; 2003 Nov 01; 9(15):1177-89. PubMed ID: 12769745
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Inhibition of glycogen phosphorylase in the context of type 2 diabetes, with focus on recent inhibitors bound at the active site.
    Praly JP, Vidal S.
    Mini Rev Med Chem; 2010 Oct 01; 10(12):1102-26. PubMed ID: 20716051
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.